Therefore, the authors have stated that the measurement of PON1 AREase activity in serum samples could be a useful diagnostic, but not prognostic, marker of COVID-19 occurrence—it has been proposed to be a simple and inexpensive tool in COVID-19 community-based diagnostics as an alternative to gold-standard detection of the viral RNA by nucleic acid amplification tests, especially in low-income countries with low levels of vaccination. The gene discussed is PON1; the disease is COVID-19.